The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
In the citing paper
“both the rarity of co-drivers and strong addiction to the ALK fusion oncoprotein may account for the long progression-free survival observed in patients with ALK-rearrangements with the potent and selective second and third generation ALK inhibitors alectinib, brigatinib and lorlatinib23, 26, 27.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citationShaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationOu, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citationALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation
Research works printed but not linked: 3
- Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
- Lu S, 2016, J Clin Oncol
- Hida T, Lancet
Cited by
Sorted by citations
Items 401–500 of 1,000
Genomic profiling in non-small-cell lung cancer in young patients. A systematic review
Viñal, D., Martínez, D., Higuera, O., & de Castro, J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100045 · Cited by 45
Wang, L., Sheng, Z., Zhang, J., Song, J., Teng, L., Liu, L., Li, Q., Wang, B., & Li, B. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1937782 · Cited by 44
Shimamura, S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., Miura, K., Mitsuishi, Y., Tajima, K., Shibayama, R., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09421-7 · Cited by 43
Cognigni, V., Pecci, F., Lupi, A., Pinterpe, G., Filippis, C. D., Felicetti, C., Cantini, L., & Berardi, R. (2022) · Cancers · doi:10.3390/cancers14194765 · Cited by 46
Nakamichi, S., Seike, M., Miyanaga, A., Chiba, M., Zou, F., Takahashi, A., Ishikawa, A., Kunugi, S., Noro, R., Kubota, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25531 · Cited by 44
Mok, T. S. K., Peters, S., Camidge, D. R., Noé, J., Gadgeel, S. M., Ou, S. I., Kim, D., Konopa, K., Pozzi, E., Liu, T., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.007 · Cited by 42
Self-citationWang, L., & Wang, W. (2020) · Oncology Reports · doi:10.3892/or.2020.7851 · Cited by 43
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E. D. C., Mitchell, E. P., Wright, J. R., Takebe, N., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00256-w · Cited by 44
Self-citationResistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Federico, A. D., Ricciotti, I., Favorito, V., Michelina, S. V., Scaparone, P., Metro, G., Giglio, A. D., Pecci, F., Lamberti, G., Ambrogio, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01436-y · Cited by 42
Sánchez-Aguilera, A., Masmudi‐Martín, M., Navas-Olivé, A., Baena, P., Hernández-Oliver, C., Priego, N., Cordón-Barris, L., Álvaro‐Espinosa, L., García‐Martín, S., Martínez, S., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.010 · Cited by 42
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers
Liang, H., Xu, Y., Zhao, J., Chen, M., & Wang, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00761-z · Cited by 45
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42
Survival and prognostic factors in surgically treated brain metastases
Kavouridis, V. K., Harary, M., Hulsbergen, A. F. C., Lo, Y. T., Reardon, D. A., Aizer, A. A., Iorgulescu, J. B., & Smith, T. R. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03171-6 · Cited by 42
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
Bebb, D. G., Banerji, S. O., Blais, N., Desmeules, P., Gill, S., Grin, A., Feilotter, H. E., Hansen, A. R., Hyrcza, M. D., Krzyzanowska, M. K., et al. (2021) · Current Oncology · doi:10.3390/curroncol28010053 · Cited by 42
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Hussain, S., Mursal, M., Verma, G., Hasan, S. S., & Khan, M. F. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176484 · Cited by 41
Overview of metastatic disease of the central nervous system
Nolan, C. P., & DeAngelis, L. M. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00001-3 · Cited by 42
The ALK receptor in sympathetic neuron development and neuroblastoma
Janoueix‐Lerosey, I., Lopez‐Delisle, L., Delattre, O., & Rohrer, H. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2784-8 · Cited by 44
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
Miura, Y., & Sunaga, N. (2018) · Cancers · doi:10.3390/cancers10080245 · Cited by 41
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Carmichael, J. A., Mak, D. W.-S., & O’Brien, M. (2018) · Cancers · doi:10.3390/cancers10070236 · Cited by 42
Alam, M. W., Borenäs, M., Lind, D. E., Cervantes-Madrid, D., Umapathy, G., Palmer, R. H., & Hallberg, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00579 · Cited by 41
Ramani, N. S., Chen, H., Broaddus, R. R., Lazar, A. J., Luthra, R., Medeiros, L. J., Patel, K. P., Rashid, A., Routbort, M. J., Stewart, J., et al. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22381 · Cited by 41
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Chang, G., Yang, T., Chen, K., Hsu, K.-H., Huang, Y.-H., Su, K., Yu, S., & Tseng, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-78152-1 · Cited by 41
Xia, P., Zhang, L., Li, P., Liu, E., Li, W., Zhang, J., Li, H., Su, X., & Jiang, G. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02982-4 · Cited by 43
Tanaka, I., Furukawa, T., & Morise, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02165-7 · Cited by 42
Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
Lehrer, E. J., Stoltzfus, K. C., Jones, B. M., Gusani, N. J., Walter, V., Wang, M., Trifiletti, D. M., Siva, S., Louie, A. V., & Zaorsky, N. G. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000866 · Cited by 41
Paz-Ares, L. G., Gondos, Á., Saldaña, D., Thomas, M., Mascaux, C., Bubendorf, L., & Barlési, F. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.021 · Cited by 42
Tamiya, Y., Matsumoto, S., Zenke, Y., Yoh, K., Ikeda, T., Shibata, Y., Kato, T., Nishino, K., Nakamura, A., Furuya, N., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.12.019 · Cited by 42
Skaugen, J. M., Taneja, C., Liu, J. B., Wald, A. I., Nikitski, A. V., Chiosea, S. I., Seethala, R. R., Ohori, N. P., French, E. K., Carty, S. E., et al. (2022) · Thyroid · doi:10.1089/thy.2022.0282 · Cited by 40
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
Kafkova, L. R., Mierzwicka, J. M., Chakraborty, P., Jakubec, P., Fischer, O., Škarda, J., Malý, P., & Raška, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342086 · Cited by 46
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Gou, Q., Gou, Q., Gan, X., & Xie, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-61087-2 · Cited by 42
Weller, M., Remón, J., Rieken, S., Vollmuth, P., Ahn, M., Minniti, G. C., Rhun, É. L., Westphal, M., Brastianos, P. K., Soo, R. A., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102807 · Cited by 40
Costa, R. B., Costa, R. L. B., Talamantes, S., Kaplan, J. B., Bhave, M. A., RADEMAKER, A. W., Miller, C. H., Carneiro, B. A., Mahalingam, D., & Chae, Y. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25154 · Cited by 40
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
Friedlaender, A., Banna, G. L., Patel, S. H., & Addeo, A. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0675-9 · Cited by 40
Decade in review: a new era for RET-rearranged lung cancers
Choudhury, N. J., & Drilon, A. E. D. C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-346 · Cited by 40
Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer
Hassanabad, A. F., & MacQueen, K. T. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00570-0 · Cited by 40
Kwon, M., Ku, B. M., Olsen, S., Park, S., Lefterova, M. I., Odegaard, J. I., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4663 · Cited by 40
Self-citationMazières, J., Iadeluca, L. L., Shaw, A. T., Solomon, B., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Kim, D., Mok, T. S. K., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.004 · Cited by 40
Self-citationLeighow, S. M., Liu, C., Inam, H., Zhao, B., & Pritchard, J. R. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.108 · Cited by 39
Dalurzo, M. L., Avilés‐Salas, A., Soares, F. A., Hou, Y., Li, Y., Строганова, А. М., Öz, B., Abdillah, A., Wan, H., & Choi, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s313669 · Cited by 39
Honda, K., Kadowaki, S., Kato, K., Hanai, N., Hasegawa, Y., Yatabe, Y., & Muro, K. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00742-2 · Cited by 39
Park, C., Kim, J.-E., Kim, M., Kho, B., Park, H.-Y., Kim, T.-O., Shin, H., Cho, H.-J., Choi, Y. D., Oh, I., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02944-w · Cited by 39
Digumarthy, S. R., Mendoza, D. P., Zhang, E. W., Lennerz, J. K., & Heist, R. S. (2019) · Cancers · doi:10.3390/cancers11122033 · Cited by 40
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 40
Role of Biomarkers and Biopsy in Hepatocellular Carcinoma
Chen, V. L., & Sharma, P. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.07.001 · Cited by 39
Borst, P. (2020) · FEBS Letters · doi:10.1002/1873-3468.13972 · Cited by 39
Buja, A., Rivera, M., Polo, A. D., Brino, E. D., Marchetti, M., Scioni, M., Pasello, G., Bortolami, A., Rebba, V. S., Schiavon, M., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13616 · Cited by 39
Sociodemographic disparities in the management of advanced lung cancer: a narrative review
Stein, J. N., Rivera, M. P., Weiner, A. A., Duma, N., Henderson, L. M., Mody, G. N., & Charlot, M. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3450 · Cited by 39
Advances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
Pulmonary Large Cell Neuroendocrine Carcinoma
Yang, L., Fan, Y., & Lu, H. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610730 · Cited by 38
Xiao, G., Li, L., Tanzhu, G., Liu, Z., Gao, X., Wan, X. H., Xiao, D., Chen, L., Xia, X., & Zhou, R. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006243 · Cited by 38
Carneiro, B. A., Pamarthy, S., Shah, A. N., Sagar, V., Unno, K., Han, H., Yang, X. J., Costa, R. B., Nagy, R. J., Lanman, R. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0332 · Cited by 38
Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients
Loganadane, G., Dhermain, F. G., Louvel, G., Kauv, P., Deutsch, É., Pechoux, C. L., & Lévy, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00336 · Cited by 38
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 40
Hofman, P. M. (2021) · Cells · doi:10.3390/cells10010168 · Cited by 38
Angeles, A. K., Christopoulos, P., Yuan, Z. K., Bauer, S., Janke, F., Ogrodnik, S. J., Reck, M., Schlesner, M., Meister, M. A., Schneider, M. A., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00239-3 · Cited by 38
Englmeier, F., Bleckmann, A., Brückl, W. M., Griesinger, F., Fleitz, A., & Nagels, K. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04034-w · Cited by 38
Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer
de Leeuw, S. P., Pruis, M. A., Sikkema, B. J., Mohseni, M., Veerman, G., Paats, M. S., Dumoulin, D. W., Smit, E. F., Schols, A. M. W. J., Mathijssen, R. H. J., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.020 · Cited by 38
Yang, Y., Min, J., Yang, N., Yu, Q., Cheng, Y., Zhao, Y., Li, M., Chen, H., Ren, S., Zhou, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01538-w · Cited by 38
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Poei, D., Ali, S., Ye, S., & Hsu, R. C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.25 · Cited by 36
Laguna, J. C., Tagliamento, M., Lambertini, M., Hiznay, J. M., & Mezquita, L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432488 · Cited by 40
Clavé, S., Rodón, N., Pijuán, L., Díaz, O., Lorenzo, M., Rocha, P., Taus, Á., Blanco, R., Bosch‐Barrera, J., Reguart, N., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.008 · Cited by 37
Wirth, L. J., Kohno, T., Udagawa, H., Matsumoto, S., Ishii, G., Ebata, K. T., Tuch, B. B., Zhu, E. Y., Nguyen, M., Smith, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00189 · Cited by 37
Andō, K., Akimoto, K., Sato, H., Manabe, R., Kishino, Y., Homma, T., Kusumoto, S., Yamaoka, T., Tanaka, A., Ohmori, T., et al. (2020) · Cancers · doi:10.3390/cancers12040942 · Cited by 37
ALK-positive Histiocytosis of the Breast
Kashima, J., Yoshida, M., Jimbo, K., Izutsu, K., Ushiku, T., Yonemori, K., & Yoshida, A. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001567 · Cited by 37
Kim, M., Suh, C. H., Lee, S. M., Park, J. E., Kim, H. C., Kim, S., Aizer, A. A., Yanagihara, T. K., Bai, H. X., Guenette, J. P., et al. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25787 · Cited by 37
Lindsay, C. R., Shaw, E. C., Moore, D. A., Rassl, D. M., Jamal‐Hanjani, M., Steele, N. L., Naheed, S., Dick, C., Taylor, F., Adderley, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01407-9 · Cited by 38
Michelotti, A., de Scordilli, M., Bertoli, E., Carlo, E. D., Conte, A. D., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126748 · Cited by 37
Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a SEER-Based Population Study
Xiong, Y., Cao, H., Zhang, Y., Zou, P., Dong, S., Wang, G., Wang, F., & Li, X. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.04.262 · Cited by 37
Zhou, F., Yang, Y., Zhang, L., Cheng, Y., Han, B., Lu, Y., Wang, C., Wang, Z., Yang, N., Fan, Y., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101560 · Cited by 37
Research progress on piperidine-containing compounds as agrochemicals
Sun, W., Liao, A., Li, L., Tang, X., Wang, Y., & Wu, J. H. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109855 · Cited by 36
Vavalà, T., & Novello, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918789364 · Cited by 36
Pawlikowska, P., Faugeroux, V., Oulhen, M., Aberlenc, A., Tayoun, T., Pailler, E., & Farace, F. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.80 · Cited by 37
Uchida, A., Seki, N., Mizuno, K., Yamada, Y., Misono, S., Sanada, H., Kikkawa, N., Kumamoto, T., Suetsugu, T., & Inoue, H. (2019) · Cancers · doi:10.3390/cancers11020258 · Cited by 36
Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma
Mian, I., Abdullaev, Z., Morrow, B., Kaplan, R. N., Gao, S., Miettinen, M., Schrump, D. S., Zgonc, V., Wei, J. S., Khan, J. I., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.11.011 · Cited by 36
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Hu, Z., Li, M., Chen, Z., Zhan, C., Lin, Z., & Wang, Q. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.10.17 · Cited by 36
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Schenk, E. L., Patil, T., Pacheco, J. M., & Bunn, P. A. (2020) · The Oncologist · doi:10.1002/onco.13590 · Cited by 37
Guidelines for clinical evaluation of anti‐cancer drugs
Minami, H., Kiyota, N., Kimbara, S., Ando, Y., Shimokata, T., Ohtsu, A., Fuse, N., Kuboki, Y., Shimizu, T., Yamamoto, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14967 · Cited by 36
Precision Dosing of Targeted Therapies Is Ready for Prime Time
Groenland, S. L., Verheijen, R. B., Joerger, M., Mathijssen, R. H. J., Sparreboom, A., Beijnen, J. H., Beumer, J. H., Steeghs, N., & Huitema, A. D. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4555 · Cited by 36
Nightingale, G., Schwartz, R. N., Kachur, E., Dixon, B. N., Cote, C., Barlow, A., Barlow, B., & Medina, P. J. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.06.008 · Cited by 36
Smolle, E., Leithner, K., & Olschewski, H. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13246 · Cited by 36
Qin, Y., Li, F., Tan, Y., Duan, Q., & Zhang, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.998545 · Cited by 35
Puri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 35
Self-citationMolecular profiling of non-small cell lung cancer
Forsythe, M. L., Alwithenani, A., Bethune, D., Castonguay, M., Drucker, A., Flowerdew, G. J., French, D., Fris, J., Greer, W., Henteleff, H., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236580 · Cited by 38
Burudpakdee, C., Wong, W. B., Seetasith, A., Corvino, F. A., Yeh, W., & Gubens, M. A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.008 · Cited by 36
Carlson, J. J., Suh, K., Orfanos, P., & Wong, W. B. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0625-6 · Cited by 35
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 36
Takahashi, K., Seto, Y., Okada, K., Uematsu, S., Uchibori, K., Tsukahara, M., Oh‐hara, T., Fujita, N., Yanagitani, N., Nishio, M., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13299 · Cited by 35
A framework for clinical and translational research in the era of rigor and reproducibility
Wichman, C., Smith, L. M., & Yu, F. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.523 · Cited by 40
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
Recondo, G., Mahjoubi, L., Maillard, A., Loriot, Y., Bigot, L., Facchinetti, F., Bahleda, R., Gazzah, A., Hollebecque, A., Mezquita, L., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00130-7 · Cited by 38
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
Kang, J., Zhang, X., Chen, H., Zhong, W., Xu, Y., Su, J., Zhou, Q. H., Tu, H., Wang, Z., Xu, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.596937 · Cited by 35
Impact of ALK Inhibitors in Patients With ALK -Rearranged Nonlung Solid Tumors
Takeyasu, Y., Okuma, H. S., Kojima, Y., Nishikawa, T., Tanioka, M., Sudo, K., Shimoi, T., Noguchi, E., Arakawa, A., Mori, T., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00383 · Cited by 36
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS
Niu, X., Chuang, J. C., Berry, G. J., & Wakelee, H. A. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0513-x · Cited by 35
Patel, S. P., Pakkala, S., Pennell, N. A., Reckamp, K. L., Lanzalone, S., Polli, A., Tarazi, J., & Robert-Vizcarrondo, F. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0034 · Cited by 34
Perioperative targeted therapy for oncogene-driven NSCLC
Liu, S. M., Zhang, J.-T., Zeng, K.-H., & Wu, Y.-L. L. C. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.007 · Cited by 34
Ernst, S. M., Hofman, M. M., van der Horst, T. E., Paats, M. S., Heijboer, F. W. J., Aerts, J. G. J. V., Dumoulin, D. W., Cornelissen, R., von der Thüsen, J. H., de Bruijn, P., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105074 · Cited by 34
Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)
Andratschke, N. H., Kraft, J., Nieder, C., Tay, R. Y., Califano, R., Soffietti, R., & Gückenberger, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.009 · Cited by 35
Cancer Treatment in the Genomic Era
Doherty, G. J., Petruzzelli, M., Beddowes, E. J., Ahmad, S. S., Caldas, C., & Gilbertson, R. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011840 · Cited by 36
Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non–Small Cell Lung Cancer
Mendoza, D. P., Lin, J. J., Rooney, M. M., Chen, T., Sequist, L. V. D., Shaw, A. T., & Digumarthy, S. R. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21982 · Cited by 35
Self-citationMetformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1
Chen, H., Lin, C., Peng, T., Hu, C., Lu, C., Li, L., Wang, Y., Han, R., Feng, M., Sun, F., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2307-5 · Cited by 34
Simons, M., Retèl, V. P., Ramaekers, B. L. T., Butter, R., Mankor, J. M., Paats, M. S., Aerts, J. G. J. V., Mfumbilwa, Z. A., Roepman, P., Coupé, V. M. H., et al. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01073-y · Cited by 34
Metadata
- Authors
- Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 829-838
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624310346
- Cited by
- 2,527
- References
- 14
- Citations by year
- 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
- FWCI
- 218.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Ariad Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Array BioPharma
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Les Laboratories Pierre Fabre
- Clovis Oncology
- G1 Therapeutics
- Eisai
- Genentech
- EMD Serono
- Ignyta
- Loxo Oncology
- Foundation Medicine
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
